Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
|Articles|April 1, 2017
Company Services
Advertisement
Patheon, a business unit of DPx Holdings B.V., is a leading provider of contract development and commercial manufacturing services to the pharmaceutical and biotechnology sectors. The company offers one of the broadest sets of solutions to customers including commercial manufacturing, drug product services, biologics, pharmaceutical development services, and active pharmaceutical ingredients.
4815 Emperor Blvd. Suite 300, Durham, NC 27703
tel. +1 919.226.3200
AAPS Biotech Booth #500
Advertisement
Related to this article
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
The half-life-extended antibody failed its primary endpoints in two Phase 2 SKYWAY sub-studies, so Spyre is dropping it in rheumatic diseases and moving it into a combination trial in hidradenitis suppurativa.
Biora will test oral adalimumab via its BioJet capsule vs injection in healthy volunteers, with dosing from December 2026 and data in early 2027.
Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near-term for options on six biologic oncology programs, deepening a partnership that began in 2024.
A former CIA officer, Pacific Research Institute economists, and industry groups say Treasury's proposed COINS Act biotechnology restrictions are too broad, while the National Security Commission on Emerging Biotechnology backs the move. Comments are due December 7, 2026.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
4
Teva Licenses US Rights to Samsung Bioepis TNF Inhibitor Biosimilars
5